Real-world overall survival after alternative dosing for pembrolizumab in the treatment of non-small cell lung cancer: A nationwide retrospective cohort study with a non-inferiority primary objective.
Geeske F GritEsmée van GeffenRuben MalmbergRoelof van LeeuwenStefan BöhringerHans Jm SmitPepijn BrockenJob Fh EijsinkEsther DronkersPim GalEva JaarsmaRegine Jhm van Drie-PierikAnne Mp Eldering-HeldensA N Machteld WymengaPeter Gm MolJuliëtte ZwavelingDoranne HilariusPublished in: Lung cancer (Amsterdam, Netherlands) (2024)
This large, retrospective real-world analysis supports the hypothesis that the alternative, partially lower pembrolizumab dosing protocol in NSCLC maintains treatment effectiveness while reducing treatment costs.